May 2023

What's bothering the pharmacist?

Products include an antidepressant and treatment for hypertension.

Products include a new FDA-approved treatment for dermatitis in younger individuals and a continuous glucose monitoring sensor system.

Adagrasib is a RAS GTPase family inhibitor with objective response rate in patients with certain types of locally advanced or metastatic non–small cell lung cancer (NSCLC).

Cases discuss triglyceride levels, supplement use, and more.

Cases address gastrointestinal issues and alcohol abuse.

Technicians should take advantage of opportunities to work at a higher level of practice, build their careers.

Eating regimen shows many health benefits, but the diet may not be appropriate for all patients.

EUA restriction for hospitalized patients was basis for lawsuit that advanced several arguments.

Death occurs from air embolism after pneumatic line was connected to an intravenous catheter.

Products include a 3-in-1 probiotic product and OTC hearing aids.

These appointments help identify medication-related problems and serve as a platform for additional education.

Federal legislation addresses variety of issues and seeks to build on gains made under the Affordable Care Act.

Teva is unable to meet demand for dextroamphetamine/amphetamine, and other companies struggle to keep up.

Options abound, but pharmacists should address barriers to prevent inequities for patients when they seek treatment.

Nonprescription products manage mild to moderate symptoms, but more severe cases need further medical evaluation.

This treatment approach helps reduce symptoms and future exacerbations triggered by dust mites, pet dander, pollen.

Recent editorial calls into question role, use of drug coverage for medications that often cost pennies to procure.

Issues highlighted in May include mental illness as well as asthma and allergies.